Lakefront Biotherapeutics NV（LKFT）财务数据LKFTLakefront Biotherapeutics NV

Evaluating the bottom line, Lakefront Biotherapeutics NV maintains a gross margin of 25.95%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -982.92%, while the net margin is 214.26%. These profitability ratios, combined with a Return on Equity (ROE) of 16.26%, provide a clear picture of how effectively LKFT converts its operational activities into shareholder value.

In the context of the broader market, LKFT competes directly with industry leaders such as ANAB and ANIP. With a market capitalization of $1.80B, it holds a leading position in the sector. When comparing efficiency, LKFT's gross margin of 25.95% stands against ANAB's 100.00% and ANIP's 54.97%. Such benchmarking helps identify whether Lakefront Biotherapeutics NV is trading at a premium or discount relative to its financial performance.

Lakefront Biotherapeutics has shown significant revenue growth, with a projected peak risk-adjusted revenue of approximately $750 million for Gamgertamig by 2040. The gross margin is exceptionally high, reaching 99.95% in Q4 2025, which indicates strong profitability potential.